[Checkpoint inhibitors in Hodgkin lymphoma]

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Classical Hodgkin lymphoma (cHL) features an immunosuppressive microenvironment.
• Hodgkin cells and macrophages interact with immune cells via programmed cell death-1 (PD-1) and programmed cell death-1 ligand-1 (PD-L1).

Purpose of the Study:

• To evaluate the role and potential of checkpoint blockade in cHL.
• Compare checkpoint blockade efficacy with standard chemo- and radiotherapy.

Main Methods:

• Analysis of preclinical data.
• Review of clinical data from Phase I and Phase II studies involving checkpoint blockade in cHL.

Main Results:

• PD-1 blockade yields responses in 60-70% of chemotherapy-refractory cHL patients.
• Excellent overall survival and persistent responses observed in a subset of patients.
• Phase II studies combining nivolumab with AVD show up to 90% response rates in first-line therapy.

Conclusions:

• Anti-PD-1 antibodies are an important treatment for relapsed cHL.
• Checkpoint blockade significantly reduces chemotherapy requirements.
• Immunomodulatory approaches represent a potential paradigm shift in cHL therapy.